A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.
- Status
- completed
- Phase
- Phase 1
- Institution
- MycoMedica Life Sciences PBC
- Start date
- 2025-07-28
- End date
- 2026-01-13
- Registry ID
- NCT07050368
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.